SBWIC
GILD icon

Schaper Benz & Wise Investment Counsel’s Gilead Sciences GILD Stock Holding History

Schaper Benz & Wise Investment Counsel’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,335
Closed -$236K – 110
2017
Q2 		$236K Buy
+3,335
New +$222K 0.04% 113

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Schaper Benz & Wise Investment Counsel's GILD Position: Q3 2017 in Review

Schaper Benz & Wise Investment Counsel sold out of Gilead Sciences (GILD) in Q3 2017, closing a stake of 3,335 shares — an estimated $236K sold.

Schaper Benz & Wise Investment Counsel first reported a position in GILD in Q2 2017 and held it in 1 quarter. The position peaked at $236K in Q2 2017. 1,504 funds tracked by Wall St. Rank hold GILD as of Q3 2017.

  • Schaper Benz & Wise Investment Counsel reported no remaining Gilead Sciences position as of Q3 2017 after selling out during the quarter.
  • Schaper Benz & Wise Investment Counsel sold 3,335 Gilead Sciences shares in Q3 2017, an estimated $236K.
  • Schaper Benz & Wise Investment Counsel first reported a position in Gilead Sciences in Q2 2017 and held it in 1 quarter.
  • Schaper Benz & Wise Investment Counsel's Gilead Sciences position peaked at $236K in Q2 2017.
  • 1,504 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2017.

Based on Schaper Benz & Wise Investment Counsel's 13F filing for Q3 2017, filed 2 Nov 2017.